Drug Use Investigation for ALLERMIST

To investigate possible problems or questions in safety and efficacy of ALLERMIST Nasal Spray in Japanese subjects with allergic rhinitis under the practical use conditions

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rhinitis Infections Nose Diseases Otorhinolaryngologic Diseases Respiratory Tract Diseases Respiratory Tract Infections

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of allergic rhinitis
Use ALLERMIST for the first time
Expected to use ALLERMIST for long-term (1 year)

Exclusion criteria

Subjects with infection which fluticasone is not effective
Subjects with deep mycosis
Subjects with hypersensitivity to fluticason

Treatment and study plan

Fluticasone

Drug

Collection of safety data

Primary outcomes

The number of adverse events in Japanese subjects with allergic rhinitis treated with fluticasone nasal spray

Time frame: Four weeks

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2011
First posted: Jun 20, 2011
Registry last updated: May 22, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed